ARA-290 Peptide – The Targeted Innate Repair Receptor Agonist
ARA-290, also known as Cibinetide, is a 11-amino acid segment that mimics the non-hematopoietic functions of erythropoietin. While standard EPO is primarily known for increasing red blood cell production, ARA-290 isolates the protein’s specialized tissue-protective and anti-inflammatory signaling pathways.
Key Research Areas:
- Neuropathic Pain & Repair: ARA-290 is a leading subject in studies involving diabetic neuropathy. Research focuses on its potential to stabilize damaged nerves and mitigate chronic pain by activating the body’s innate repair mechanisms.
- Selective Receptor Targeting: Unlike EPO, ARA-290 does not bind to the homodimeric EPO receptor. Instead, it selectively targets the Innate Repair Receptor (IRR), which is typically expressed only during tissue injury or inflammation, making it a “smart” target for regenerative medicine.
- Anti-Inflammatory & Immunomodulation: Studies in models of Systemic Lupus Erythematosus (SLE) and other autoimmune conditions suggest that ARA-290 may suppress pro-inflammatory cytokines while promoting an anti-apoptotic environment for compromised cells.
- Wound Healing & Permeability: Researchers investigate ARA-290 for its anti-permeability characteristics, exploring how it might prevent “leaky” vascular structures and improve the healing rate of complex neuropathic wounds.
- Neuroprotection: Beyond pain, the peptide is evaluated for its capacity to protect neurons from metabolic stress and programmed cell death, positioning it as a critical tool for neurodegenerative research.
Elite Peptide Supply provides high-purity ARA-290 (Cibinetide) for laboratory experimentation. Our peptide is synthesized to ensure the ZEQLERALNSS sequence remains highly stable for accurate mapping of non-erythropoietic EPO pathways.
Reviews
There are no reviews yet.